TechTalk: Bioanalytical strategy for parallel total and conjugated antibody quantification for novel ADCs
Thursday, September 24 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
Antibody-drug conjugates (ADC) are a rapidly expanding class of therapeutics, especially within oncology. The complex nature of the ADC requires additional pharmacokinetic (PK) assays, including quantification of total antibody (tAb) and conjugated antibody (cAb).
In this Tech Talk, Dr. Valeria Castagna from Merck, Italy, will describe how parallel testing and validation of assays to measure tAb and cAb on Gyrolab®, saved time and sample volumes in ADC drug development, without compromising the data quality.
Certificate of attendance
If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand TechTalk, you can request a certificate of attendance by emailing editor@selectscience.net.
TechTalk details
- Cost: Free to attend
- Location: Online
- Duration: 20 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available
Speakers
Who should attend?
- Bioanalytical scientists and laboratory leads (CROs and pharma)
- Heads of bioanalysis/PK/DMPK
- CRO operational and scientific directors
- Assay development and Method transfer teams
- Project managers responsible for bioanalytical timelines
Featured products
Request Quote for All Products
Gyrolab xPlore™ immunoassay system
Gyros Protein TechnologiesGyrolab xPlore is a single-CD, cost-effective microfluidic immunoassay platform for unattended parallel processing of 96 or 112 data points in one hour.
Gyrolab® xPand immunoassay system
Gyros Protein TechnologiesGyrolab xPand is a high-throughput, compact disk (CD) based microfluidic immunoassay platform for unattended parallel processing of up to 5 CDs, generating 560 data points in 5 hours.
What will this webinar cover?
- How a large pharmaceutical company adopts a parallel validation strategy for simultaneous tAb and cAb method validation on Gyrolab® – including the single MRD preparation approach, plate-splitting workflow, and how multi-run instrument configurations (Gyrolab xPand or multiple xPlore units) support same-day execution.
- How the company achieved efficiency gains from parallel vs. sequential validation – validation time reduced by approximately half, matrix and reagent consumption halved, and fewer operators required over a shorter engagement period.
- Insight into total antibody (tAb) and conjugated antibody (cAb) as separate bioanalytical analytes in ADC programmes – understand what each measures, why both are required, and how they relate to DAR distribution and in vivo payload stability.